Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
ACS Appl Mater Interfaces ; 13(29): 33905-33914, 2021 Jul 28.
Artículo en Inglés | MEDLINE | ID: mdl-34278780

RESUMEN

Coencapsulation of chemotherapeutic agents and photosensitizers into nanocarriers can help to achieve a combination of chemotherapy and photodynamic therapy for superior antitumor effects. However, precise on-demand drug release remains a major challenge. In addition, the loaded photosensitizers usually tend to aggregate, which can significantly weaken their fluorescent signals and photodynamic activities. To address these issues, herein, a smart nanocarrier termed as singlet oxygen-responsive nanoparticle (SOR-NP) was constructed by introducing singlet oxygen (1O2)-sensitive aminoacrylate linkers into amphiphilic mPEG-b-PCL copolymers. Boron dipyrromethene (BDP) and paclitaxel (PTX) as model therapeutic agents were coloaded into an 1O2-responsive nanocarrier for realizing light-controlled drug release and combination cancer treatment. This polymeric nanocarrier could substantially relieve the aggregation of encapsulated BDP due to the presence of a long hydrophobic chain. Therefore, the formed SOR-NPBDP/PTX nanodrug could generate bright fluorescent signals and high levels of 1O2, which could mediate cell death via PDT and rupture aminoacrylate linker simultaneously, leading to collapse of SOR-NPBDP/PTX and subsequent PTX release. The light-triggered drug release and combined anticancer effects of SOR-NPBDP/PTX were validated in HepG2 and MCF-7 cancer cells and H22 tumor-bearing mice. This study provides a promising strategy for tumor-specific drug release and selective photodynamic-chemo combination treatment.


Asunto(s)
Antineoplásicos/uso terapéutico , Portadores de Fármacos/química , Nanopartículas/química , Neoplasias/tratamiento farmacológico , Fármacos Fotosensibilizantes/uso terapéutico , Acrilatos/síntesis química , Acrilatos/química , Animales , Antineoplásicos/química , Compuestos de Boro/química , Compuestos de Boro/uso terapéutico , Línea Celular Tumoral , Portadores de Fármacos/síntesis química , Liberación de Fármacos , Femenino , Humanos , Ratones , Paclitaxel/química , Paclitaxel/uso terapéutico , Fotoquimioterapia , Fármacos Fotosensibilizantes/química , Poliésteres/síntesis química , Poliésteres/química , Polietilenglicoles/síntesis química , Polietilenglicoles/química , Pirroles/química , Pirroles/uso terapéutico , Oxígeno Singlete/metabolismo
2.
Lin Chuang Er Bi Yan Hou Ke Za Zhi ; 17(2): 84-5, 2003 Feb.
Artículo en Zh | MEDLINE | ID: mdl-12833689

RESUMEN

OBJECTIVE: In order to investigate the treatment of obstructive sleep apnea syndrome (OSAS) METHOD: The improved uvulopalatopharyngoplasty (UPPP) operations were performed on 64 cases. RESULT: The clinical results showed that 70. Thirty-one percent of the operated patients somewhat improved and 29. Seventy percent unimproved. CONCLUSION: UPPP is one of the effective methods to treat OSAS, especially for OSAS with stricture in pharyngeal cavity. It has less damage, less operative complications and so on.


Asunto(s)
Paladar Blando/cirugía , Faringe/cirugía , Apnea Obstructiva del Sueño/cirugía , Úvula/cirugía , Adulto , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Procedimientos Quirúrgicos Orales/métodos , Procedimientos Quirúrgicos Otorrinolaringológicos/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA